1. Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
   Chao Chen et al, 2021, Frontiers in Oncology CrossRef
2. Network pharmacology-based prediction and experimental verification of the involvement of the PI3K/Akt pathway in the anti-thyroid cancer activity of crocin
   Yan Tang et al, 2023, Archives of Biochemistry and Biophysics CrossRef
3. Advances of Epigenetic DNA Methylation and Histone Modifications in DLBCL
   ·米吉提 木提拜尔, 2024, Advances in Clinical Medicine CrossRef
4. Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
   Oliver H. Krämer et al, 2022, Clinical and Translational Medicine CrossRef
5. Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
   Junnan Kang et al, 2021, Journal of Cellular and Molecular Medicine CrossRef
6. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy
   Han‐Yu Cao et al, 2023, Hematological Oncology CrossRef
7. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma
   Linyan Xu et al, 2023, Journal of Pharmacology and Experimental Therapeutics CrossRef
8. Targeting HDACs for diffuse large B-cell lymphoma therapy
   Chunyan Wu et al, 2024, Scientific Reports CrossRef
9. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma
   Kehui Zhang et al, 2022, Bioorganic & Medicinal Chemistry Letters CrossRef
10. Epigenetic alterations and advancement of lymphoma treatment
    Shuhui Zhuang et al, 2024, Annals of Hematology CrossRef
11. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
    Varun Monga et al, 2021, Journal for ImmunoTherapy of Cancer CrossRef